Early-stage biotech Camino Pharma is a San Diego-based startup with a small team (2-10 employees) focused on first-in-class cancer and CNS therapies, representing an attractive collaboration target for specialized contract research, early discovery partnerships, and sponsored research agreements.

Grant and SBIR leverage Recent SBIR funding of $1.97M from the National Institute of Alcohol Abuse and Alcoholism indicates access to non-dilutive capital and potential for government-funded research programs; opportunities exist to align with their grant pursuits or co-fund translational studies.

Strategic partnerships Past collaboration with Sanford Burnham Prebys suggests openness to joint research initiatives; potential sales opportunities include outsourced discovery services, target biology consulting, and shared-risk development programs with academic and research partners.

Tech-enabled agility Utilizing cloud and modern web tooling signals a lean, tech-savvy operation; sales conversations can emphasize scalable, cloud-based data management, compliance-friendly CRO partnerships, and rapid integration with their existing digital infrastructure.

Growth through collaborations With modest revenue and total funding, Camino Pharma appears poised for strategic partnerships, license deals, or milestone-based collaborations with larger biotechs or CROs aiming to access novel signaling targets in oncology and CNS spaces.